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Abstract
Background and Objective: Recently, we demonstrated that angiotensin II (AngII)-infusion profoundly increased both
aortic protein and activity of calpains, calcium-activated cysteine proteases, in mice. In addition, pharmacological inhibition
of calpain attenuated AngII-induced abdominal aortic aneurysm (AA) in mice. Recent studies have shown that AngII infusion
into mice leads to aneurysmal formation localized to the ascending aorta. However, the precise functional contribution of
calpain isoforms (-1 or -2) in AngII-induced abdominal AA formation is not known. Similarly, a functional role of calpain in
AngII-induced ascending AA remains to be defined. Using BDA-410, an inhibitor of calpains, and calpain-1 genetic deficient
mice, we examined the relative contribution of calpain isoforms in AngII-induced ascending and abdominal AA
development.
Methodology/Results: To investigate the relative contribution of calpain-1 and -2 in development of AngII-induced AAs,
male LDLr 2/2 mice that were either calpain-1 +/+ or 2/2 were fed a saturated fat-enriched diet and infused with AngII
(1,000 ng/kg/min) for 4 weeks. Calpain-1 deficiency had no significant effect on body weight or blood pressure during AngII
infusion. Moreover, calpain-1 deficiency showed no discernible effects on AngII-induced ascending and abdominal AAs.
Interestingly, AngII infusion induced increased expression of calpain-2 protein, thus compensating for total calpain activity
in aortas of calpain-1 deficient mice. Oral administration of BDA-410, a calpain inhibitor, along with AngII-infusion
significantly attenuated AngII-induced ascending and abdominal AA formation in both calpain-1 +/+ and 2/2 mice as
compared to vehicle administered mice. Furthermore, BDA-410 administration attenuated AngII-induced aortic medial
hypertrophy and macrophage accumulation. Western blot and immunostaining analyses revealed BDA-410 administration
attenuated AngII-induced C-terminal fragmentation of filamin A, an actin binding cytoskeletal protein in aorta.
Conclusion: Calpain-2 compensates for loss of calpain-1, and both calpain isoforms are involved in AngII-induced aortic
aneurysm formation in mice.
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Introduction
Ascending and abdominal aortic aneurysms (AAs) are two
major common aortic diseases that have highly distinct patholo-
gies, and mediated by different etiologies [1]. Ascending AAs are
highly associated with genetic abnormalities of connective tissue
and frequently occur in younger individuals [2,3]. Abdominal AAs
show relatively weak genetic association, but are positively
associated with aging, male gender and smoking [4–6]. Since
both ascending and abdominal AAs are asymptomatic, the
incidence of aortic rupture is increasing and the current therapy
is restricted only to surgical repair.
Chronic infusion of angiotensin II (AngII) into hypercholester-
olemic mice promotes atherosclerosis and abdominal AA forma-
tion [7–9]. Recently, it was recognized that AngII-infusion also
leads to aneurysmal formation localized to the ascending aorta
[10]. Although AngII infusion develops both ascending and
abdominal AAs in the same mouse model, the underlying
pathologies are clearly distinct between the two forms. AngII-
induced abdominal AAs are characterized with initial small focal
regions of macrophage accumulation in the aortic media [11].
AngII-induced ascending AAs are characterized with macrophage
accumulation throughout the aortic circumference, predominantly
on the adventitial side of the aorta [10]. Systemic deficiency of
angiotensin II type 1a (AT1a) receptor completely ablates the
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development of AngII-induced ascending and abdominal AAs in
mice [12,13]. However, identities of key regulators and underlying
mechanisms for development of these vascular pathologies remain
poorly understood.
Recently, we demonstrated that pharmacological inhibition of
calpain, a calcium dependent cysteine protease, using a novel and
relatively specific inhibitor, BDA-410, significantly attenuated
AngII-induced abdominal AA formation in LDLr2/2 mice [14].
BDA-410 is an active synthetic Leu-Leu peptidomimetic with a
cyclopropenone group that strongly binds to the hydrogens of the -
SH residues of cysteines contained in the calpain molecule [15,16].
BDA-410 has a potent and selective inhibitory action on calpain
over other proteases. In cultured SHSY5Y cells, the inhibitory
effects against specific proteases (IC50) are calpain 1/calpain
2= 21 nM; papain= 400 nM; cathepsins B= 16,000 nM; throm-
bin .100 mM; cathepsin G, D and proteasome 20S .100 mM.
The beneficial effect of calpain inhibition on abdominal AA
formation was mainly associated with a reduction in medial
macrophage accumulation and inflammation [14]. The two major
isoforms of the calpain family, calpain-1 and calpain-2, are
ubiquitously expressed along with their endogenous inhibitor,
calpastatin, whereas other isoforms such as calpain-3, calpain-8,
and calpain-9 show tissue-specific expression [17]. However, the
precise functional contribution of either calpain isoform, in the
development of AngII-induced abdominal AA formation remains
unknown. Similarly, a functional role of calpain activity in the
development of AngII-induced ascending AA remains to be
defined. Using the pharmacological inhibitor of calpains, BDA-
410, and calpain-1 genetic deficient mice, we examined the
relative contribution of calpain-1 and -2 isoforms in development
of AngII-induced ascending and abdominal AAs. Our findings
demonstrate a functional role of both calpain isoforms in
development of AngII-induced vascular pathology.
Methods
Ethics Statement
This study followed the recommendations of The Guide for the
Care and Use of Laboratory Animals (National Institutes of
Health). All mouse studies were performed with approval by the
University of Kentucky’s Institutional Animal Care and Use
Committee (Protocol# 2011-0907). The mice were observed daily
for any signs of distress and weighed weekly to monitor health.
Pump implantation was conducted using isoflurane inhalation
anesthesia, and termination was performed with overdose of
ketamine/xylazine.
Mice
LDL receptor 2/2 (stock # 002207) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). Calpain-1 2/2
mice on a C57BL/6 background were originally generated in the
laboratory of Dr. Athar Chishti [18,19]. LDL receptor 2/2 and
calpain-12/2 mice were backcrossed 10 times into the C57BL/6
background. To generate study mice in an LDL receptor 2/2
background, calpain-1 2/2 males were mated to LDL receptor
2/2 females, and their offspring were bred to generate calpain-
1+/2 males and females in the LDL receptor 2/2 genotype.
Subsequent breeding generated relevant littermate controls of
calpain-1 +/+ x LDL receptor 2/2 and calpain-1 2/2 x LDL
receptor 2/2 mice. Age-matched male littermates (8–10 weeks
old) were used for the present study. Mice were maintained in a
barrier facility and fed normal mouse laboratory diet. All study
Figure 1. Calpains are present in AngII-induced abdominal
AAs. Cross-sections from the abdominal aorta of LDLr 2/2 mice
infused with AngII for 28 days were immunostained with anti-mouse
calpain-1/-2 (A–D) or with cell-specific markers. Immunostaining with
rat anti-mouse CD68 or rabbit anti-sera for mouse macrophages (E–H),
rabbit a-SMC actin for SMCs (I,J), and ERTR-7 for fibroblasts (K,L). Arrow
indicates positive red staining. Scale bars correspond to 50 mm. A,C,E,G,I
and K= 1006; B,D,F,H,J and L = 2006.
doi:10.1371/journal.pone.0072214.g001
Table 1. Effects of calpain-1 deficiency in male LDL receptor
2/2 mice infused with AngII.
Groups Calpain-1 +/+ Calpain-1 2/2
N 20 21




Systolic BP Pre-infusion (mmHg) 12264 12366
Systolic BP Post-infusion (mmHg) 15665* 15366*
Values are represented as means 6 SEMs. Body weights and plasma cholesterol
concentrations were determined at termination. One way repeated measures
ANOVA was used to analyze systolic blood pressures.
*Denotes P,0.001 systolic BP post-infusion vs pre-infusion, by one-way
repeated measures ANOVA. There were no significant differences between the
calpain-1 genotypes for body weight, plasma cholesterol and systolic BP.
doi:10.1371/journal.pone.0072214.t001
Calpain Function in Aortic Aneurysms
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procedures were approved by the University of Kentucky
Institutional Animal Care and Use Committee.
Mouse Genotyping
Mouse genotypes were confirmed by PCR. DNA was isolated
from tail snips using a DNeasy tissue kit (Cat# AS1120, Promega,
Madison, WI). Calpain-1 genotyping was performed using the
following primers: 5’-TGCACTCTAGTTCTGAGG CT-3’, 5’-
AGAGTGCACGAACACCAGCTT-3’, and 5’-TTAAGGGC-
CAGCTCATTCCT-3’. PCR of wild-type and disrupted alleles
generated amplicons of 615 bp and 415 bp, respectively. A
representative gel of calpain-1 +/+ and 2/2 amplicons is shown
in the Figure S1 in File S1. LDL receptor genotyping was
performed as described previously [20].
Diet
To induce hypercholesterolemia, mice were fed a diet
supplemented with saturated fat (21% wt/wt milk fat;
TD.88137, Harlan Teklad, Indianapolis, IN) for 2–5 weeks.
Calpain Inhibitor BDA-410 Administration
BDA-410 was a kind gift from the Mitsubishi Tanabe Pharma
Corporation, Osaka, Japan. The BDA-410 compound was
pulverized and suspended in 1% Tween 80 diluted in saline and
administered daily for 2 or 5 weeks by gavage at a dose of 30 mg/
kg/day [15].
AngII Infusion
After an initial week of high-fat diet feeding, mice were
implanted with Alzet osmotic minipumps (model 1004 or 2004,
Durect Corporation, Cupertino, CA), subcutaneously into the
right flank, and infused with AngII (1,000 ng/kg/min, Bachem,
Torrance, CA) continuously for a period of 7,14 or 28 days, as
described previously [7]. Mice were maintained on high fat-
enriched diet throughout the study. For calpain inhibition studies,
along with high fat diet and AngII infusion, mice were gavaged
daily with the calpain inhibitor, BDA-410.
Blood Pressure Measurement
Systolic blood pressure (SBP) was measured noninvasively on
conscious mice by volume pressure recording of the tail using a
computerized tail cuff blood pressure system (Kent Scientific Corp,
Torrington, CT) [21]. SBP was measured on 5 consecutive days
prior to pump implantation, and during the last 5 days of the
AngII infusion.
Measurement of Plasma Components
Plasma cholesterol concentrations were measured using a
commercially available enzymatic kit (Wako Chemicals, Rich-
mond, VA) and lipoprotein cholesterol distribution was deter-
mined as described previously [7,20].
Ultrasound Imaging of Abdominal AA
Luminal dilation of the abdominal aorta was measured by a
high frequency ultrasound imaging system (Vevo 2100, Visual
Sonics, Toronto, Canada) using a MS400 MicroScanTM trans-
ducer with a resolution frequency of 18–38 MHz [22]. Mice were
anesthetized and restrained in a supine position to acquire
ultrasonic images. Short axis scans of abdominal aortas were
performed from the left renal arterial branch level to the
suprarenal region [22]. Images of abdominal aortas were acquired
and measured to determine maximal diameter in the suprarenal
Figure 2. Calpain-1 deficiency had no effect on AngII-induced
abdominal AA formation. A. Ultrasonic measurements of abdominal
aortic diameters were measured on day 0 and after 28 days of AngII-
infusion (n = 15–20). B. Measurements of maximal external width of
abdominal aortas on day 28 (n = 20–21). Open circles (calpain-1 +/+)
and gray circles (calpain-1 2/2) represent individual mice, diamonds
represent means, and bars are SEMs. Statistical analyses were
performed using repeated measures ANOVA with a Holm-Sidak
multiple comparison post-hoc test (A), or nonparametric Mann-Whitney
Rank sum test (B). * denotes P,0.05 when comparing saline versus
AngII-infused mice.
doi:10.1371/journal.pone.0072214.g002
Figure 3. Calpain-1 deficiency had no effect on AngII-induced
ascending AA formation. Measurements of ascending aortic arch
intimal area after 28 days of AngII-infusion (n = 17–19). Open circles
(calpain-1 +/+) and gray circles (calpain-1 2/2) represent individual
mice, diamonds represent means, and bars are SEMs. Statistical analyses
were performed using nonparametric Mann-Whitney Rank sum test.
doi:10.1371/journal.pone.0072214.g003
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region of the abdominal aorta. Aortic images were acquired at day
0 and 28 of AngII-infusion.
Quantification of Atherosclerosis and Ascending and
Abdominal AAs
Atherosclerosis was quantified on aortic arches as lesion area on
the intimal surface by en face analysis as described previously
[23,24]. For aneurysm measurements, after saline perfusion
through the left ventricle of the heart, aortas were removed from
the origin to iliac bifurcation, and placed in formalin (10% wt/vol)
overnight. Adventitial fats were cleaned from the aortas. Abdom-
inal AAs were quantified ex vivo by measuring the maximum
external width of the suprarenal abdominal aortic diameter using
computerized morphometry (Image-Pro Cybernetics, Bethesda,
MD) as described previously [25]. For ascending AA measure-
ment, aortas were cut open longitudinally from the inner arch
curvature to the iliac bifurcation, as well as from the outer
curvature to the subclavian branch. Aortas were pinned and
photographed using a Nikon Digital Camera (DXM1200). Intimal
areas of ascending aortas were measured from the ascending aorta
to the subclavian branch using Image-Pro Plus software [10,12].
Tissue Histology and Immunostaining
Ascending and abdominal aortas were placed in OCT and
sectioned (10 mm thickness/section) in sets of 10 slides serially with
9 sections/slide by a cryostat [12]. One of the slides was stained
with Movat’s pentachrome (Polyscientific) and measurements were
performed to determine medial thickness and elastin breaks. To
quantify medial thicknesses, every section from each slide was
measured perpendicular from internal to external elastic lamina
[12]. Immunohistochemical staining was performed on AA
sections to detect calpain-1, calpain-2, macrophages, smooth
muscle cells, fibroblasts and endothelial cells. Calpain-1 and -2
immunostaining were performed using the rabbit anti-mouse
calpain-1 and -2 (aminoterminal end domain-I, 3 mg/ml, catalog
Nos. RP1-Calpain-1 and RP-2 Calpain-2; Triple Point biologics,
Forest Grove, OR). The following reagents were used to detect
specific cell types: rat anti-mouse CD68 (1:200, catalog No.
MCA1957; Serotec, Raleigh, NC) and rabbit antisera (1:1000,
catalog No. AI-AD31240; Accurate Chemical, Westbury, NY) for
macrophages; rabbit anti-mouse a-smooth muscle actin (2 mg/ml,
catalog No: ab5694; Abcam, Cambridge, MA) for smooth muscle
cells; rat anti-mouse reticular fibroblasts and reticular fibers (1 mg/
ml, catalog No: ab51824; Abcam, Cambridge, MA) for fibroblasts.
Figure 4. Elevated calpain protein in AngII infused calpain-1 +/+ and calpain-1 2/2 aortas. Calpain-1 (A) and calpain-2 (B) proteins were
detected by Western blotting in tissue extracts from aortas in calpain-1 +/+ x LDL receptor 2/2 and calpain-1 2/2 x 2/2 LDL receptor 2/2 mice
infused with either saline or AngII for 7 days. b-actin was shown as loading control. Calpain-1 (A) and calpain-2 (B) protein abundance was quantified
by image analysis. Images are representative out of 4 independent experiments. Results are represented as means 6 SEMs; Statistical analyses were
performed using Students t test (A) or two-way ANOVA with a Holm-Sidak multiple comparison post-hoc test (B). * represent significance of P,0.05.
doi:10.1371/journal.pone.0072214.g004
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Figure 5. Elevated calpain activity in AngII infused calpain-1 +/+ and calpain-1 2/2 aortas. Spectrin breakdown products (A) were
detected by Western blotting in tissue extracts from aortas in calpain-1 +/+ x LDL receptor 2/2 and calpain-1 2/2 x 2/2 LDL receptor 2/2 mice
infused with either saline or AngII for 7 days as a measure of calpain activity. b-actin was shown as loading control. Calpain activity (B) was also
measured by a fluorimetric assay in aortic tissue extracts from saline and AngII infused calpain-1 +/+ and 2/2 mice (n = 4). Calpastatin (C) was
detected by Western blotting in aortic tissue extracts. Spectrin (A) and calpastatin (C) protein abundance was quantified by image analysis. Images
are representative out of 4 independent experiments. Results are represented as means 6 SEMs; Statistical analyses were performed using two-way
ANOVA with a Holm-Sidak multiple comparison post-hoc test (A–C). * and horizontal bars represent significance of P,0.05.
doi:10.1371/journal.pone.0072214.g005
Calpain Function in Aortic Aneurysms
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In addition we also attempted to immunostain for endothelium
using rat anti-mouse platelet endothelial cell adhesion molecule
(PECAM)-1 (CD31, 1:1000; catalog No. 553371; BD Pharmin-
gen, San Jose, CA ) and rabbit anti-mouse CD31 (1:100; catalog
No. RB-10333-P1; Lab Vision Corporation, Fremont, CA) and for
spectrin using rabbit anti-mouse spectrin (1 mg/ml; catalog No.
A301-249A, Bethyl Laboratories, Montgomery, TX). Immuno-
staining was performed on formalin-fixed frozen sections, with
appropriate negative controls, as described previously [20,26].
Western Blot Analyses
Whole aortic tissue lysates were extracted in radio immunopre-
cipitation assay (RIPA) lysis buffer and protein content was
measured using the Bradford assay (Bio-Rad, Hercules, CA).
Protein extracts (30 mg) were resolved by SDS-PAGE (6 or 7.5%
wt/vol) and transferred electrophoretically to PVDF membranes.
After blocking with non-dry fat milk (5% wt/vol), membranes
were probed with primary antibodies. The following antibodies
against calpain-1 domain IV (catalog No: ab39170), calpain-2
(catalog No: ab39165) and filamin A (catalog No: ab76289) were
purchased from Abcam, Cambridge, MA. Spectrin (catalog No:
MAB1622) antibody was purchased from Chemicon-EMD
Millipore, Billerica, MA. Calpastatin (catalog No. PA5-17068)
antibody was purchased from Pierce, Rockford, IL. b-actin
(catalog No: A5441) antibody was purchased from Sigma-Aldrich,
St. Louis, MO. Membranes were incubated with appropriate
HRP-labeled secondary antibodies, immune complexes were
visualized by chemiluminescence (Pierce, Rockford, IL) and
quantified using a Kodak Imager.
Calpain Activity Assay
Calpain enzyme activity was measured in aortic tissue lysates
fluorimetrically using a commercially-available activity assay kit
(Calpain, catalog No: K240-100; BioVision, Mountain View, CA).
Aortic protein extracts (20 mg) were incubated with fluorogenic (4-
trifluoromethyl coumarin labeled) calpain substrate for 60 min at
37uC. Mean fluorescence signals were measured using a micro-
plate fluorescent plate reader (Spectramax M2; Molecular
Devices, Sunnyvale, CA) as per manufacturer’s instructions.
Statistical Analyses
Data are represented as mean 6 SEM. Statistical analyses were
performed using SigmaPlot 12.0 (SYSTAT Software Inc., San
Jose, CA, USA). Repeated measurement data were analyzed with
SAS fitting a linear mixed model expressing the temporal trend in
systolic blood pressure as a quadratic polynomial in time for each
treatment. Ultrasound measurements of abdominal aortic diam-
eter measured on day 0 and day 28 were analyzed using one or
two way repeated measures ANOVA. Student’s t test or Mann-
Whitney Rank Sum test was performed as appropriate for two-
group comparisons. Two way ANOVA with Holm-Sidak post hoc
analysis was performed for multiple-group and multiple-manipu-
lation analysis. Values of P,0.05 were considered to be
statistically significant.
Results
Calpains are Present in AngII-induced Abdominal AAs
Immunostaining using calpain-1, -2 and cell specific antibodies
were performed on AngII-induced abdominal AA sections to
examine the distribution and localization of calpains in abdominal
AAs. Positive immunostaining for calpain-1 and -2 (Fig. 1A–D)
Table 2. Effects of BDA-410 administration on calpain-1
deficiency in male LDL receptor 2/2 mice infused with AngII.
Groups Calpain-1 +/+ Calpain-1 2/2
Drug Vehicle BDA-410 Vehicle BDA-410
N 13 12 12 12
Body Weight (g) 3261 3361 3261 3061
Plasma Cholesterol
(mg/dL)
1434684 1647696 1661699 1558665
Values are represented as means 6 SEMs. Body weights and plasma cholesterol
concentrations were determined at termination. There were no significant
differences between the calpain-1 genotypes for body weight and plasma
cholesterol concentrations.
doi:10.1371/journal.pone.0072214.t002
Figure 6. BDA-410 administration attenuated AngII-induced
abdominal aortic luminal dilation and expansion in calpain-1
deficient mice. A. Ultrasonic measurements of abdominal aortic
diameters of calpain-1 +/+ and 2/2 mice administered with either
vehicle or BDA-410 were measured on day 0 and after 28 days of AngII-
infusion (n = 10–12). B. Measurements of maximal external width of
abdominal aortas on day 28 (n = 10–12). Open circles (calpain-1 +/+)
and gray circles (calpain-1 2/2) represent individual mice, diamonds
represent means, and bars are SEMs. Statistical analyses were
performed using repeated measures ANOVA (A), or Two way ANOVA
with a Holm-Sidak multiple comparison post-hoc test (B). Horizontal
bars represent significance of P,0.05 when comparing day 0 and day
28. * denotes P,0.05 when comparing vehicle versus BDA-410.
doi:10.1371/journal.pone.0072214.g006
Calpain Function in Aortic Aneurysms
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was most pronounced in regions containing macrophages (Fig. 1E–
H). Diffused immunostaining was also observed in the aortic
media (Fig. 1I,J) and adventitia (Fig. 1K,L).
Calpain-1 Deficiency had No Effect on AngII-induced
Abdominal AAs
To determine the role of calpain-1 in AngII-induced abdominal
AA formation, male LDL receptor 2/2 mice with either calpain-
1 +/+ or 2/2 genotype were fed a high fat-enriched diet, and
infused with AngII (1,000 ng/kg/min) for 28 days. AngII infusion
significantly increased SBP in both groups (P,0.001; Table 1).
Calpain-1 deficiency or AngII-infusion had no effect on body
weight, plasma total cholesterol concentrations (Table 1), or
lipoprotein cholesterol distribution (Figure S2 in File S1). AngII-
infusion significantly increased luminal dilation of abdominal
aortas as measured by ultrasound on day 28 compared to day 0 in
both animal groups (P,0.05; Fig. 2A). However, there was no
significant difference between the two groups at 28 days. In
addition, calpain-1 deficiency did not influence the formation of
AngII-induced abdominal AA as measured by ex vivo external
aortic width (Fig. 2B). Examples of ultrasound photographs and ex
vivo images of abdominal aortas are shown in the Figures S3 A and
B. Moreover, calpain-1 deficiency did not exert any significant
Figure 7. BDA-410 administration suppressed abdominal aortic medial disruption in calpain-1 +/+ and 2/2 mice. Representative
suprarenal aortic tissue-sections from AngII+vehicle (A–D) and AngII+BDA-410 (E–H) administered calpain-1 +/+ and calpain-1 2/2 mice stained
with Movat’s pentachrome. Arrow indicates medial break. Scale bars correspond to 50 mm. A,C,E and G=406; B,D,F and H= 2006.
doi:10.1371/journal.pone.0072214.g007
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effect on AngII-induced atherosclerosis. Atherosclerosis lesion size
was quantified on the intimal surface of the aortic arch (Figure S4
in File S1).
Histological features of aortic medial breaks in the abdominal
aortas were examined by Movat’s Pentachrome staining (Figures
S5 A-D in File S1). Furthermore, immunostaining using CD68
antibodies was performed to examine macrophage accumulation.
AngII infusion showed occurrence of focal elastin disruption in
abdominal aortas that was associated with accumulation of
CD68+ macrophages (Figures S5 E-H in File S1). However, the
effects were comparable between calpain-1 +/+ and 2/2 mice.
Calpain-1 Deficiency had No Effect on AngII-induced
Ascending AAs
Recently, it has been reported that chronic AngII infusion also
induces ascending AAs. [10] Here, we examined the effect of
calpain-1 deficiency on AngII-induced ascending AAs. Dilation of
the ascending aortas was determined by measuring intimal area of
the ascending aorta. No significant differences were observed
between the two different genotypes (Fig. 3). Examples of ex vivo
images of ascending arch area are shown in the Figure S3 C in File
S1.
Histology (Movat’s Pentachrome) and CD68 immunostaining
on ascending aortic sections showed occurrence of focal elastin
Figure 8. BDA-410 administration reduced macrophage accumulation in abdominal aortas of calpain-1 +/+ and 2/2 mice.
Representative suprarenal aortic tissue-sections from AngII+vehicle (A–D) and AngII+BDA-410 (E–H) administered calpain-1 +/+ and calpain-1 2/2
mice immunostained for CD68 (E–H). CD68+ cells stain red. Arrow indicates positive staining with CD68. Scale bars correspond to 50 mm. A,C,E and
G= 406; B,D,F and H= 2006.
doi:10.1371/journal.pone.0072214.g008
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disruption (Figures S6 A-D in File S1) associated with CD68+
macrophage accumulation (Figures S6 E-H in File S1). However,
the effects were comparable between the two groups of mice.
AngII Infusion Increased Calpain-2 Protein Abundance
and Compensated Aortic Calpain Activity in Calpain-1
Deficient Mice
Since calpain-1 deficiency had no effect on AngII-induced
ascending and abdominal AAs, we investigated the possibility
whether loss of calpain-1 may be compensated by an increase of
calpain-2 during AngII infusion. Male LDL receptor 2/2 mice
that were either calpain-1 +/+ or 2/2 genotype were fed a high
fat-enriched diet and infused with either saline or AngII (1000 ng/
kg per minute) for 7 days. Aortas were minced and protein content
was extracted using a lysis buffer. Western blotting using a calpain-
1 specific antibody demonstrated that AngII-infusion increased
calpain-1 protein abundance in calpain-1 +/+ mice and none in
calpain-1 2/2 aortas, further phenotypically confirming the
deficient genotype (Fig. 4A). Similarly, Western blotting using a
calpain-2 specific antibody showed that basal level of calpain-2
was similar between calpain-1 +/+ and 2/2 mice infused with
saline. Interestingly, AngII infusion significantly increased calpain-
2 protein abundance in aortas of calpain-1 2/2 mice, not in
calpain-1 +/+ mice (Fig. 4B). To further confirm whether
increased calpain-2 protein compensates for total calpain activity
in aortas of calpain-1 deficient mice, breakdown product of
spectrin, the major substrate of calpain, [27,28] was analyzed by
Western blot. Western blotting using a spectrin specific antibody
demonstrated slightly reduced breakdown of spectrin in aortas
from calpain-1 2/2 mice infused with saline. However, AngII
infusion showed a comparable significant increase in spectrin
breakdown product in both calpain-1 +/+ and 2/2 mice
(Fig. 5A). The increased calpain activity was further confirmed
by measuring calpain activity in aortic tissue extracts using a
fluorescent substrate of calpain, Ac-LLY-AFC. AngII infusion
showed a comparable 2-fold increase in calpain activity in both
calpain-1 +/+ and 2/2 mice compared to the saline group
(Fig. 5B). These results demonstrate that increased calpain-2
protein compensates for total calpain activity in calpain-1 deficient
mice during AngII infusion. In addition, Western blot analyses
using antibodies against calpastatin, an endogenous inhibitor of
calpains, [29,30] revealed that AngII infusion significantly
suppressed calpastatin protein abundance in aortas of both
calpain-1 +/+ and 2/2 mice (Fig. 5C).
Administration of a Calpain Inhibitor, BDA-410,
Attenuated AngII-induced Abdominal AA Formation in
both Wild Type and Calpain-1 Deficient Mice
To determine whether compensatory increase of calpain-2
contributes to development of AngII-induced AAs in calpain-1
deficient mice, male LDL receptor 2/2 mice that were either
calpain-1 +/+ or 2/2 fed with a high fat enriched diet were
infused with either saline or AngII (1000 ng/kg per minute) for 28
days. The calpain inhibitor, BDA-410, was administered at a dose
of 30 mg/kg per day by oral gavage 1 week before infusion and
throughout the subsequent 28 days [14]. Administration of BDA-
410 had no effect on body weight and plasma total cholesterol
concentrations (Table 2). AngII infusion significantly increased
luminal dilation of abdominal aortas in vehicle-administered
calpain-1 +/+ and 2/2 groups, as measured by ultrasound on
day 28 (P,0.05; Fig. 6A). In contrast, administration of BDA-410
significantly attenuated AngII-induced luminal dilation of abdom-
inal aortas in both calpain-1 +/+ and 2/2 groups (P,0.05;
Fig. 4A). Inhibition of calpain activity by BDA-410 significantly
attenuated the formation (P,0.05; Fig. 6B) of AngII-induced
abdominal AA in both calpain-1 +/+ and 2/2 mice.
Histology and immunostaining of abdominal aortas using
Movat’s Pentachrome staining and anti-CD68 antibodies respec-
tively revealed occurrence of focal elastin layer disruption (Fig. 7
A–D) associated with the accumulation of CD68+ macrophages
(Fig. 8 A–D) with AngII infusion in both calpain-1 +/+ and 2/2
groups. However, administration of calpain inhibitor, BDA-410,
along with AngII infusion preserved the medial elastin layer (Fig.7
E–H), and attenuated macrophage accumulation (Fig. 8 E–H) in
the abdominal aorta of both groups.
Administration of Calpain Inhibitor, BDA-410, Attenuated
AngII-induced Ascending AA Formation in both Wild
Type and Calpain-1 Deficient Mice
Next we examined the effect of BDA-410 administration on
AngII-induced ascending AA formation in both calpain-1 +/+ and
2/2 mice. Dilation of ascending aortic intimal area was
measured as an index of severity of aneurysm. AngII infusion
increased ascending aortic area in vehicle-administered calpain-1
+/+ and 2/2 mice to a similar extent (Fig. 9A). In contrast,
administration of BDA-410 significantly attenuated AngII-induced
Figure 9. BDA-410 administration attenuated AngII-induced
ascending aorta dilation and aortic medial thickness in
calpain-1 deficient mice. A. Measurement of intimal areas of
ascending aortas on day 28 (n = 10–12). B. Measurement of medial
thickness measured from internal to external lamina (n = 10–12). Open
circles (calpain-1 +/+) and gray circles (calpain-1 2/2) represent
individual mice, diamonds represent means, and bars are SEMs.
Statistical analyses were performed using Two way ANOVA with a
Holm-Sidak multiple comparison post-hoc test. * denotes P,0.05 when
comparing vehicle versus BDA-410.
doi:10.1371/journal.pone.0072214.g009
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ascending aorta dilation in both calpain-1 +/+ and 2/2 groups
(P,0.05; Fig. 9A). In addition, AngII infusion increased ascending
aortic medial thickness (Fig. 9B) as measured from inner to outer
elastic lamina. As reported earlier, Movat’s pentachrome staining
showed that increased aortic medial thickness is associated with an
expansion of intraelastic spaces towards the adventitial aspect of
the media (Fig. 10 A–D). Movat’s staining also showed that AngII-
induced medial thickness in the intra-lamellar medial space was
associated with the deposition of proteoglycans and glycosamino-
glycans (Fig. 10 A–D). Further, immunostaining for macrophages
using a CD68 antibody, showed the accumulation of CD68+
macrophages in the expanded intra-lamellar medial space (Fig. 11
A–D). Administration of BDA-410 significantly attenuated AngII-
induced medial thickness (P,0.05; Fig. 9B), extracellular matrix
and macrophage accumulation in the ascending aortas of both
calpain-1 +/+ and 2/2 mice (Fig. 10 E–H, Fig. 11 E–H).
Calpain Inhibition Attenuated AngII-induced Filamin-A
Breakdown in the Aorta
A recent proteomic analysis study using aortic medial tissue
protein extract from Marfan Syndrome patients showed upregula-
tion of the C-terminal fragmentation of filamin A, that was highly
correlated with elevated calpain-2 activity [31]. Filamin A, an
Figure 10. BDA-410 administration suppressed ascending aortic medial break in calpain-1 +/+ and 2/2 mice. Representative anterior
ascending aortic tissue sections from AngII+vehicle (A–D) and AngII+BDA-410 (E–H) administered calpain-1 +/+ and calpain-1 2/2 mice stained
with Movat’s pentachrome. Arrow indicates medial break. Scale bars correspond to 50 mm. A,C,E and G=406; B,D,F and H= 2006.
doi:10.1371/journal.pone.0072214.g010
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actin binding protein, is known to be required for cell-cell contact
during vascular development. Filamin A protein also contributes
to organization and stability of the actin cytoskeleton, integrates
cellular signaling cascades, and regulates cellular functions
including adhesion and motility [32]. Therefore, we examined
whether AngII infusion increases the C-terminal fragmentation of
filamin A in the aorta and whether BDA-410 administration had
any influence on this process. Male LDL receptor 2/2 mice fed a
high fat-enriched diet were infused with either saline or AngII for
14 days. The calpain inhibitor, BDA-410, was administered at a
dose of 30 mg/kg per day by gavage one week before infusion and
throughout the subsequent 14 days. AngII infusion significantly
increased C-terminal fragmentation of filamin A as analyzed by
Western blotting using an antibody specific for the C-terminal
domain of filamin A (P,0.05; Fig. 12). In contrast, BDA-410
administration along with AngII significantly blunted AngII-
induced filamin A fragmentation in the aortas (P,0.05; Fig. 12).
Discussion
In the present study, we examined the role of calpain-1 in
AngII-induced ascending and abdominal AAs. Here, we demon-
Figure 11. BDA-410 administration reduced macrophage accumulation in ascending aortas of calpain-1 +/+ and 2/2 mice.
Representative anterior ascending aortic tissue sections from AngII+vehicle (A–D) and AngII+BDA-410 (E–H) administered calpain-1 +/+ and calpain-
1 2/2 mice immunostained for CD68 (E–H). CD68+ cells stain red. Arrow indicates positive staining with CD68. Scale bars correspond to 50 mm.
A,C,E and G= 406; B,D,F and H= 2006.
doi:10.1371/journal.pone.0072214.g011
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strated that calpain-1 deficiency had no discernible effects on
AngII-induced ascending and abdominal AAs. Administration of a
calpain specific inhibitor, BDA-410, significantly attenuated
AngII-induced ascending and abdominal AA formation in both
calpain-1 +/+ and 2/2 mice. The beneficial effect of calpain
inhibition was associated with the reduction of macrophage
accumulation, and blunted the AngII-induced C-terminal frag-
mentation of actin binding protein, filamin A, in the aorta.
Calpain-1 deficiency did not show any effects on AngII-induced
blood pressure elevation. Consistent with the current observation,
our earlier study of calpain inhibition using BDA-410 also showed
no effect on AngII-induced increased blood pressure [14]. This
result is in agreement with an earlier study in which overexpres-
sion of calpastatin attenuated AngII-induced cardiac hypertrophy
without affecting blood pressure [33]. Further, development of
AngII-induced abdominal or ascending AAs is shown to be
independent of increases in blood pressure [34,10].
In the present study, whole body deficiency of calpain-1 had no
influence on size and incidence of either AngII-induced abdominal
or ascending AAs. However, administration of calpain inhibitor,
BDA-410, significantly attenuated development of AngII-induced
vascular pathologies. These findings indicate that complete
inhibition of calpain activity is required to attenuate AngII-
induced AAs. An interesting finding here is the observation that
during AngII infusion, calpain-1 deficiency is associated with an
increase in calpain-2 protein abundance. In addition, elevated
level of calpain-2 contributed to total aortic calpain activity in
calpain-1 deficient mice compared to calpain-1 +/+ aortas, as
evident by increased breakdown of its substrate protein, spectrin,
and also by increased hydrolysis of fluorescent labeled calpain
substrate. AngII infusion into wild type mice had no effect on
calpain-2 protein abundance in the aorta, which is consistent with
our earlier findings showing that AngII infusion into hypercho-
lesterolemic mice increased aortic calpain-1, but not calpain-2,
protein and activity [14]. These observations clearly demonstrate
that there is a compensatory increase of calpain-2 by AngII in
calpain-1 deficient mice to maintain the total aortic calpain
activity. However, it is not clear whether the two calpain isoforms,
-1 and -2, are acting synergistically or independently in mediating
development of AngII-induced AAs. Given the fact that calpain-1
deficiency had no effect on AngII-induced aortic pathologies,
depletion of calpain-2 itself may be sufficient to attenuate
development of AngII-induced AAs. However, embryonic lethality
of calpain-2 deficiency in mice impedes development of whole
body calpain-2 deficient mice. Recently, calpain-2 floxed mice
have been developed, that will serve as a unique tool to study the
role of cell specific calpain-2 in development of AngII-induced
AAs [35]. In support of a specific role of calpain-2 in development
of ascending AAs, a proteomics study of aortic media in patients
with Marfan syndrome revealed a higher level of calpain-2 protein
and calpain activity [31]. Increased calpain activity was positively
correlated with fragmentation of actin binding protein filamin A in
the dilated aortic media [31].
Macrophages are one of the major leukocytic components
present in both AngII-induced ascending and abdominal AAs
[10,11]. Similar to our earlier studies [14] and other published
reports, [11] AngII promoted medial macrophage accumulation in
the abdominal aortas. In contrast, ascending aortas from calpain-1
+/+ and 2/2 mice showed considerable accumulation of
macrophages throughout the intralamellar spaces on the adven-
titial site of the vessel. In agreement, previous studies also
demonstrated increased macrophage accumulation on the adven-
titial side of the ascending aorta with AngII infusion [12,10].
Consistent with our previous study, BDA-410 administration
attenuated macrophage accumulation in abdominal aortas as well
as ascending aortas of both groups of mice. The beneficial effect
observed with calpain inhibition on initial macrophage accumu-
lation raises a question of possible involvement of leukocytic-
derived calpains in development of AngII-induced vascular
pathologies. However, bone marrow transplantation studies using
AT1a receptor deficient mice failed to demonstrate a role of bone
marrow-derived AT1a receptors in the development of AngII-
induced ascending and abdominal AAs [12,13]. In fact, these
studies suggested involvement of AT1a receptors present in the
resident vessel wall cells. With respect to ascending AAs, depletion
of AT1a receptors in endothelial cells, not in smooth muscle cells,
partially reduced ascending aortic dilation [12]. Also deficiency of
CCR2, the cognate receptor of MCP-1, suppressed AngII-induced
ascending aortic dilation to a similar extent as observed with
endothelial AT1a receptor deficient mice [10]. Based on these
studies, calpain-derived from aortic endothelial cells may be
involved in the breakdown of aortic medial tissue by enhancing the
C-terminal fragmentation of actin binding protein filamin A and
thereby promoting ascending aorta dilation.
In support of this hypothesis, proteomics analysis of aortic
media protein from Marfan syndrome patients showed increased
fragmentation of filamin A protein with positive correlation of
increased calpain activity [31]. Although filamin A can be cleaved
Figure 12. BDA-410 administration attenuated AngII-induced C-terminal fragmentation of filamin A in aortas of LDL receptor 2/2
mice. Filamin A protein was detected by Western blotting in aortic tissue extracts from saline and AngII infused mice administered either vehicle or
BDA-410 (n = 4). b-actin was shown as the loading control. Results are represented as means 6 SEMs; Statistical analyses were performed using two-
way ANOVA with a Holm-Sidak multiple comparison post-hoc test. * represent significance of P,0.05 when vehicle compared to BDA-410.
doi:10.1371/journal.pone.0072214.g012
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by caspase activity as well as granzyme B, proteomics analysis
showed no alterations in activity of either caspase or granzyme B
in the aortic media of Marfan syndrome patients [31]. This
observation further supports the potential effect of calpain activity
on filamin A degradation in Marfan patients. In a published
abstract, Kim and Dietz groups have reported a recurrent mis-
sense mutation at the calpain cleavage site of filamin A in patients
with ascending AA. Furthermore, they also demonstrated that in
cells isolated from ascending AA patients, calpain inhibition
blocked transforming growth factor-b induced epithelial to
mesenchymal transition, thus preserving epithelial cell morphology
[36]. In our present study, we also observed an increased C-
terminal fragmentation of filamin A with AngII-infusion in aortas.
In support to the above mentioned clinical reports, administration
of calpain inhibitor, BDA-410, completely attenuated the C-
terminal fragmentation of filamin A by AngII. Altogether, these
findings strongly support a possible role of increased calpain
activity in filamin A degradation in development of AngII-induced
ascending AA.
In summary, using calpain-1 deficient mice and a novel calpain
inhibitor, BDA-410, we demonstrate a functional role of calpain
activity in development of AngII-induced ascending and abdom-
inal AAs. Inhibition of calpain activity may offer a new therapeutic
target to prevent aortic dilation in patients with Marfan syndrome
and abdominal AA. However, further studies are warranted to
evaluate the specific role of calpain-2 and the cellular sources of
calpain activity in development of AngII-induced AAs. The recent
availability of calpain-2 floxed mice will be helpful to identify the
source and functional role of calpain-2 in future studies.
Supporting Information
File S1 File includes Figures S1–S6. Figure S1. Genotyping
of experimental mice for calpain-1 alleles by PCR. Genomic DNA
from tail biopsies was isolated and screened by PCR for calpain-1
wild type (+/+) and null (2/2) alleles. Reaction products were
sized using agarose gel electrophoresis. Figure S2. Calpain-1
deficiency did not affect lipoprotein cholesterol distributions.
Lipoproteins were resolved by size-exclusion chromatography.
Total cholesterol concentrations are expressed as mean absor-
bance per fraction. Symbols represent the means and bars are
SEMs of 5 individual mice per group: Calpain-1 +/+ (circles) and
calpain-1 2/2 (triangles). Figure S3. Examples of vascular
pathology measurements. Ultrasound images (A - Day 0 and
Day 28), ex vivo pictures of suprarenal aortas (B - after
termination) and ascending arch aortas (C), that represent aortic
diameters nearest the mean of each group. Figure S4. Calpain-1
deficiency had no effect on AngII-induced atherosclerosis in LDL
receptor 2/2 mice. Atherosclerotic lesion areas were measured
on aortic arch intimal surfaces (n = 18–19). Open circles (calpain-1
+/+) and gray circles (calpain-1 2/2) represent individual mice,
diamonds represent means, and bars are SEMs. Statistical analyses
were performed with nonparametric Mann-Whitney Rank sum
test. Figure S5. Histological and cellular characteristics of AngII-
induced abdominal AAs in calpain-1 +/+ and calpain-1 2/2
mice. Representative suprarenal aortic tissue-sections from AngII
infused calpain-1 +/+ and calpain-1 2/2 mice stained with
Movat’s pentachrome (A–D) and immunostained for CD68 (E–H).
Elastin stains black; CD68+ cells stain red. Scale bars corresponds
to 50 mm. Arrow indicates medial break and positive staining with
CD68. A,C,E and G=406; B,D,F and H=2006. Figure S6.
Histological and cellular characteristics of AngII-induced ascend-
ing AAs in calpain-1 +/+ and calpain-1 2/2 mice. Representa-
tive anterior ascending aortic tissue-sections from AngII infused
calpain-1 +/+ and calpain-1 2/2 mice stained with Movat’s
pentachrome (A–D) and immunostained for CD68 (E–H), Elastin
stains black; CD68+ cells stain red. Scale bars corresponds to
50 mm. Arrow indicates medial break and positive staining with
CD68. A,C,E and G=406; B,D,F and H=2006.
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